Introduction
============

Ferritin, neuron-specific enolase (NSE), lactate dehydrogenase (LDH), and the catecholamine metabolites, vanillylmandelic acid (VMA) and homovanillic acid (HVA), are commonly assessed in children suspected to have neuroblastoma (NB), and the levels of these markers are commonly used for differential diagnosis.[@b1-ott-5-417] Several studies performed over more than 3 decades[@b2-ott-5-417]--[@b7-ott-5-417] have suggested that they may have a prognostic value, but the small numbers of patients studied in each cohort have hampered the possibility to assess their role independent from stage, age, and *MYCN* status, which are the established parameters to stratify patients.[@b1-ott-5-417] Only Berthold et al[@b6-ott-5-417] demonstrated an independent prognostic role of plasma VMA/HVA ratio in patients with localized NB, but this finding was of limited interest since catecholamine metabolites are commonly measured in urine rather than in plasma. Methodological issues further limited the power of previous reports. Analyses were often performed at the home institutions rather than at a national reference laboratory, and unavoidable methodological changes occurred over the years.

Recently, it has been shown that the presence of either structural or numerical aberrations in the genome of primary NB tumor cells can predict outcome of low- and intermediate-risk NB patients.[@b8-ott-5-417],[@b9-ott-5-417] Thus, multicenter studies are currently stratifying patients in different protocol arms depending on these features, (see <http://www.siopen-net.org> ). These analyses, however, require a primary tumor biopsy and are costly and time-consuming.

Thus, we decided to retrieve all the results obtained at the Italian reference laboratory where all the analyses for the various markers have been centralized since 1994, and check whether any of these markers was an independent predictor of survival.

Patients and methods
====================

The study cohort includes all patients diagnosed in Italy with NB, according to the International Neuroblastoma Staging System (INSS) criteria,[@b10-ott-5-417] between June 1994 and November 2010, for whom at least one diagnostic analysis was performed at the Italian reference laboratory located at the Gaslini Institute. None of the patients included were diagnosed by mass screening. Moreover, no modifications of the INSS criteria have occurred during the study period. The demographic, clinical and follow-up data (at January 2011) of the 505 study patients (109 stage 1, 39 stage 2, 92 stage 3, 217 stage 4, and 48 stage 4S) were retrieved from the Italian NB Registry.[@b11-ott-5-417]

Laboratory analysis
-------------------

Urinary HVA and VMA concentrations were determined on samples derived from 24-hour urine collections. Urinary and plasma HVA and VMA were performed by gas chromatography coupled to mass spectrometry (GC-MS) as described by Hunneman.[@b12-ott-5-417] Since 2006 urinary HVA and VMA were analyzed by high-pressure liquid chromatography coupled with electrochemical detection (HPLC-EC), using a commercially available method (HVA-VMA by HPLC; Bio Rad Laboratories, Milan, Italy). Urinary HVA and VMA concentrations were expressed as a ratio to creatinine concentration, previously determined using the Jaffè method. LDH, NSE, and ferritin were determined on heparinized plasma, using routine clinical chemistry laboratory methods. Sensitivity and specificity of urinary HVA and VMA are reported in Monsaingeon et al[@b13-ott-5-417]; sensitivity of plasma HVA, VMA, NSE, and LDH in Simon et al[@b14-ott-5-417]; specificity of NSE in Viallard et al[@b15-ott-5-417]; whereas ferritin and LDH are nonspecific markers.

Treatment
---------

After diagnosis the study patients were treated according to the Italian Neuroblastoma protocols,[@b11-ott-5-417],[@b16-ott-5-417]--[@b18-ott-5-417] until the commencement of the various International Society of Pediatric Oncology European Neuroblastoma Group (SIOPEN) protocols.[@b19-ott-5-417]--[@b22-ott-5-417] All protocols were approved by the local Institutional Review Boards. Before being enrolled, and treated on their respective trials, patients or their guardians signed a consent form allowing the use of their clinical and genetic data for clinical research. No other specific informed consent was required for the purposes of this study.

Statistical analysis
--------------------

For each marker, statistical analysis was first performed on the entire cohort of the study patients. Then patients were grouped according to the following variables: stage (localized, metastatic NB), age (≤18 months, .18 months), and *MYCN* status (not amplified, amplified). Differences were assessed by Mann--Whitney *U* test or Fisher's exact test. Correlations were estimated by the Pearson's coefficient. Cumulative survival was calculated by the Kaplan--Meier procedure using the first quartile of the marker distribution as cut-off value to stratify the patients. For event-free survival plots, the occurrence of relapse, progression, or death were considered as an event. Statistical significance was estimated by log rank test. Multivariate analysis was performed by the Cox regression method by including only the significant variables.

Results
=======

In the study period, a total of 1717 children were diagnosed with NB in Italy. Of these, 505 patients had at least one urinary or plasma marker analyzed at diagnosis at the Italian reference laboratory. As shown in [Table 1](#t1-ott-5-417){ref-type="table"}, where the demographic, biological and clinical features of the study patients are summarized, no significant differences were found between the study patients and the entire population of NB patients diagnosed in Italy during the study period. Moreover, the event-free and overall survival (EFS and OS) of the study patients, stratified by stage, age, *MYCN* status, and treatment protocol was similar to that of the entire population.[@b11-ott-5-417]

The results obtained for each marker in the entire study cohort are summarized in [Table 2](#t2-ott-5-417){ref-type="table"}. Of the 411 patients that had urinary HVA and VMA determined, 174 had also plasma catecholamine determined. Correlation between urinary and plasma values was high (HVA: Pearson's correlation coefficient = 0.19, *P* \< 0.05; VMA: Pearson's correlation coefficient = 0.25, *P* \< 0.01), confirming previous findings.[@b6-ott-5-417],[@b23-ott-5-417] As reported previously,[@b2-ott-5-417],[@b7-ott-5-417],[@b24-ott-5-417],[@b25-ott-5-417] the median levels of VMA and HVA increased by stage and the higher levels were found in stage 4S infants (251 and 215 μg/mg creatinine, respectively, with a median ratio of 1.41).

Values for ferritin, NSE, and LDH were available for half of the study patients, but overlapping with urinary HVA and VMA was relatively low (N = 162).

Prognostic values of urinary and plasmatic VMA/HVA ratio
--------------------------------------------------------

VMA and HVA are the end product of two different pathways of catecholamine catabolism, thus their relative abundance seems to associate with different phenotypes, each characterized by different prognosis.[@b2-ott-5-417],[@b26-ott-5-417]--[@b28-ott-5-417] Indeed, plasma VMA/HVA ratio was shown to be predictive in localized patients.[@b6-ott-5-417] In our cohort, univariate analysis demonstrated that neither VMA nor HVA had any prognostic value, even when patients with localized and metastatic disease were considered separately. However, in patients with localized NB, both urinary and plasma VMA/HVA ratio positively associated with a better outcome ([Table 3](#t3-ott-5-417){ref-type="table"}). Patients with urinary VMA/HVA ratio \< 0.50 had 3.44 times greater chance of relapse than patients with a ratio ≥ 0.50 (95% confidence interval \[CI\]: 1.26--9.39; *P* \< 0.05). Most importantly, multivariate analysis demonstrated that in patients with localized disease without *MYCN* amplification, urinary VMA/HVA ratio \< 0.5 and plasma VMA/HVA ratio \< 0.15 were independent predictors of poor prognosis ([Figure 1A and B](#f1-ott-5-417){ref-type="fig"}, respectively; *P* = 0.017 for both).

Prognostic value of ferritin
----------------------------

Ferritin was evaluated in 272 patients ([Table 2](#t2-ott-5-417){ref-type="table"}). In the whole cohort of patients, univariate analysis indicated a significant positive association between ferritin values higher than the first quartile value and a worse EFS ([Figure 1C](#f1-ott-5-417){ref-type="fig"}; *P* \< 0.01). However, multivariate analysis demonstrated that ferritin levels positively associated with stage, thus eliminating its predictive power ([Table 3](#t3-ott-5-417){ref-type="table"}).

Prognostic value of NSE
-----------------------

Neuron-specific enolase was evaluated in 233 patients ([Table 2](#t2-ott-5-417){ref-type="table"}). When the entire cohort of patients was considered, NSE did not associate with EFS or OS. However, in stage 4 patients NSE levels \< 200 ng/mL associated with a better EFS ([Table 3](#t3-ott-5-417){ref-type="table"}). Multivariate analysis confirmed that the NSE levels were an independent predictor of prognosis in stage 4 patients without *MYCN* amplification ([Table 3](#t3-ott-5-417){ref-type="table"} and [Figure 1D](#f1-ott-5-417){ref-type="fig"}; *P* \< 0.01).

Prognostic value of LDH
-----------------------

Lactate dehydrogenase was evaluated in a total of 279 patients. Both in patients with localized and metastatic disease, high LDH values positively associated with a worse prognosis (*P* \< 0.01). In particular, patients with localized disease with LDH values \> 1300 IU/mL had 12.9 times greater chance of relapse (95% CI: 3.34--49.78; *P* \< 0.001). However, multivariate analysis confirmed LDH predictive power only in patients without *MYCN* amplification ([Table 3](#t3-ott-5-417){ref-type="table"} and [Figure 1E](#f1-ott-5-417){ref-type="fig"}; *P* = 0.0001). In stage 4 patients, the LDH cut-off value discriminating patients with good and bad prognosis was 2500 IU/mL ([Table 3](#t3-ott-5-417){ref-type="table"}). Also, in stage 4 patients LDH was an independent prognostic factor only in patients without *MYCN* amplification ([Figure 1F](#f1-ott-5-417){ref-type="fig"}; *P* = 0.0001).

Discussion
==========

The aim of this work was to investigate the independent prognostic value of different markers commonly evaluated at diagnosis in NB patients as a potential tool to stratify patients in different risk groups. The availability of a routine test, performed at diagnosis in peripheral blood or urine samples, may reduce the time and cost of prognostic analyses with respect to those performed on primary tumors.[@b8-ott-5-417],[@b9-ott-5-417]

In our study, LDH values above 1300 IU/mL in patients with localized disease and above 2500 IU/mL in stage 4 patients were positively associated with a worse outcome, independent of age and stage. LDH levels, however, were positively associated with *MYCN* amplification. Thus, in prospective trials for patients with localized disease without *MYCN* amplification, LDH levels at diagnosis should be evaluated for their predictive power as compared to the genetic tests performed on the primary tumors. An association between LDH levels and outcome of patients with localized disease was also observed in the Localised Neuroblastoma European Study, but no multivariate analysis was performed.[@b19-ott-5-417] Similarly, the Task Force of the International Neuroblastoma Risk Group[@b29-ott-5-417] found that a single LDH cut-off level of 587 IU/mL could dichotomize NB patients into good and poor prognosis. However, LDH was not included in the new INRG Staging System because of its unspecific nature.

Our study demonstrated that in patients with localized disease without *MYCN* amplification, urinary and plasmatic VMA/HVA ratio were also positively associated with a better event-free survival. In 1992, Berthold et al[@b6-ott-5-417] demonstrated that plasma VMA/HVA ratio was an independent predictor of EFS for patients with localized disease. Although Gahr and Hunneman[@b23-ott-5-417] had shown a good agreement between urinary and plasma catecholamine levels, urinary levels were globally measured. Thus, the report did not receive proper attention.

As first reported by Laug et al[@b2-ott-5-417] and confirmed by several groups,[@b7-ott-5-417],[@b24-ott-5-417],[@b25-ott-5-417] a higher VMA/HVA ratio was found in stage 4S infants. VMA and HVA are the byproducts of two distinct catecholamine metabolic pathways starting from norepinephrine and dopa, respectively. Gitlow et al[@b30-ott-5-417] first suggested that high HVA levels were produced by undifferentiated, unfavorable prognosis tumors. Kontras[@b31-ott-5-417] showed that high VMA levels correlated to a more differentiated phenotype with better prognosis. In our study, information on the differentiation of the primary tumors was not available, thus precluding any study of association. However, our multivariate analysis confirmed the association between low VMA levels and *MYCN* amplification,[@b25-ott-5-417]--[@b28-ott-5-417] and added weight to the association between low VMA levels and poor prognosis previously found in smaller cohorts of NB patients.[@b2-ott-5-417],[@b4-ott-5-417],[@b24-ott-5-417]

Our multivariate analysis, performed separately in patients with metastatic and localized disease, also explained the contrasting results found in these two subsets of patients by Aydin et al[@b7-ott-5-417] with regard to the association of VMA levels with outcome. In fact, the frequency of *MYCN* amplification in stage 4 patients is higher than in localized patients, whose VMA levels increase from stage 1 to stage 3. In view of this effect, the use of VMA/HVA ratio had greater advantage with respect to the use of VMA alone.

As for the other two markers evaluated in our study, ferritin association with outcome was dependent on the stage of disease, whereas NSE levels \> 200 ng/mL positively associated with a worse outcome only in stage 4 patients without *MYCN* amplification, thus limiting their utility in patient risk stratification.

It is important to note that in our study about 30% of the NB patients had unknown *MYCN* status, thus the association of each marker with *MYCN* status must be taken with caution. Further validation of our findings in a future prospective study is needed.

Conclusion
==========

Urinary and plasma VMA/HVA ratio \> 0.5 and 0.15, respectively, and LDH values \< 1300 IU/mL were found to be independent predictors of good prognosis in patients with localized NB without *MYCN* amplification. Thus, these data, commonly determined at diagnosis in all NB patients, should be collected in future protocols for this subset of patients, and their prognostic value compared to that of structural and numerical chromosomal aberrations present in the primary tumors.
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![Kaplan--Meier plots of event-free survival of (**A**) patients with localized NB stratified by urinary VMA/HVA cut-off value; (**B**) patients with localized disease stratified by plasma VMA/HVA cut-off value; (**C**) the entire cohort of study patients stratified by ferritin cut-off value; (**D**) patients with stage 4 disease stratified by NSE cut-off value; (**E**) patients with localized disease stratified by LDH cut-off value; and (**F**) patients with stage 4 disease stratified by LDH cut-off value.\
**Note:** For each marker the cut-off value corresponded to the first quartile of the marker distribution in that group of patients.\
**Abbreviations:** HVA, homovanillic acid; LDH, lactate dehydrogenase; NB, neuroblastoma; NSE, neuron-specific enolase; VMA, vanillylmandelic acid.](ott-5-417f1){#f1-ott-5-417}

###### 

Demographic, biological and clinical features of the study patients stratified by stage, and comparison with the whole NB population diagnosed during the study period

  Study patients      Stage   NB patients   *P*                                                 
  ------------------- ------- ------------- ------- ------- ------- ------------- ------------- --------
  N                   109     39            92      217     48      505           1717          
  **Sex**                                                                                       
  Female              42      21            49      87      21      220 (43.6%)   764 (44.5%)   NS
  Male                67      18            43      130     27      285 (56.4%)   953 (55.5%)   
  **Age**                                                                                       
  ≤18 months          57      25            48      56      48      234 (46.3%)   855 (49.8%)   NS
  ***MYCN* status**                                                                             
  Normal              48      23            33      28      37      169 (72.2%)   606 (70.9%)   NS
  Amplified           2       1             12      18      5       38 (16.2%)    90 (10.5%)    NS
  Not known           7       1             3       10      6       27 (11.6%)    159 (18.6%)   \<0.01
  5 years EFS         96.7%   100%          88.5%   45.9%   75.0%   76.9%         77.8%         NS
  5 years OS          98.2%   100%          92.5%   56.1%   81.3%   82.9%         85.2%         NS
  \>18 months         52      14            44      161     --      271 (53.7%)   862 (50.2%)   NS
  *MYCN* status                                             --                                  
  Normal              27      10            16      86      --      139 (51.3%)   433 (50.2%)   NS
  Amplified           2       2             15      31      --      50 (18.4%)    123 (14.3%)   \<0.05
  Not known           23      2             13      44      --      82 (30.3%)    306 (35.5%)   NS
  5 years EFS         100%    83.3%         63.6%   22.5%   --      38.2%         37.6%         NS
  5 years OS          100%    92.9%         75.2%   30.1%   --      50.6%         50.8%         NS

**Abbreviations:** NB, neuroblastoma; NS, not significant; EFS, event-free survival; OS, overall survival.

###### 

Concentration of each analyte in the entire cohort of study patients (N = 505) and in patients with localized disease (N = 288)

  N                                               VMA/creatinine (μg/mg)   HVA/creatinine (μg/mg)   Plasma VMA (ng/mL)   Plasma HVA (ng/mL)   Ferritin (ng/mL)   NSE (ng/mL)   LDH (IU/mL)
  ----------------------------------------------- ------------------------ ------------------------ -------------------- -------------------- ------------------ ------------- -------------
  **Study patients (N = 505)**                                                                                                                                                 
  Valid                                           411                      402                      174                  174                  272                233           279
  Missing                                         94                       103                      331                  331                  233                272           226
  Mean                                            167.5                    195.1                    318.9                1265.9               262.7              130.2         1653.3
  Median                                          53.0                     73.6                     98.0                 553.5                119.5              56.6          912.0
  Standard deviation                              320.5                    542.2                    792.9                2434.1               407.9              175.5         2104.9
  Percentiles                                                                                                                                                                  
   25                                             14.4                     25.2                     39.0                 205.0                47.25              23.1          579.0
   50                                             53.0                     73.6                     98.0                 553.5                119.5              56.6          912.0
   75                                             180.6                    209.6                    295.4                1367.7               280.2              169.2         1727.0
  **Patients with localized disease (N = 288)**                                                                                                                                
  Valid                                           227                      226                      93                   93                   155                132           159
  Missing                                         61                       62                       195                  195                  133                156           129
  Mean                                            144.6                    125.9                    278.1                795.5                150.4              80.7          1259.8
  Median                                          30.7                     41.2                     64.0                 269.0                69.0               30.2          687.0
  Standard deviation                              319.0                    204.1                    793.7                1321.8               214.7              115.3         1637.6
  Percentiles                                                                                                                                                                  
   25                                             10.4                     19.3                     33.5                 154.7                26.0               17.1          513.0
   50                                             30.7                     41.2                     64.0                 269.0                69.0               30.3          687.0
   75                                             100.7                    128.1                    172.3                880.8                193.0              93.7          1334.0

**Abbreviations:** HVA, homovanillic acid; LDH, lactate dehydrogenase; NSE, neuron-specific enolase; VMA, vanillylmandelic acid.

###### 

Prognostic value of each marker in the different groups of neuroblastoma patients

  *MYCN*                      Patients with localized NB   Patients with metastatic NB   Cut-off value                                                              
  --------------------------- ---------------------------- ----------------------------- --------------- ----------- ---------- ----------- ----------- ----------- ----------------------------------------------------
  **Urinary VMA/HVA ratio**                                                                                                                                         0.50
  N total                     111                          13                            41              10          22         14          66          26          
  Mean                        1.28                         0.55                          0.76            0.57        1.32       0.30        1.09        0.71        
  N (%) over cut-off          14 (12.6)                    8 (61.5)                      14 (34.1)       6 (60.0)    5 (22.7)   11 (78.6)   15 (22.7)   17 (65.4)   
  Association with outcome    Y                            N                             Y               N           N          N           N           N           
  *P*                         0.017                                                                                  NS                                             
  **Plasma VMA/HVA ratio**                                                                                                                                          0.15
  N total                     46                           6                             25              4           5          7           50          9           
  Mean                        0.59                         0.13                          0.29            0.09        0.24       0.11        0.34        0.11        
  N (%) over cut-off          5 (10.9)                     5 (83.3)                      6 (24.0)        4 (100.0)   3 (60.0)   6 (85.7)    19 (38.0)   8 (88.9)    
  Association with outcome    Y                            N                             Y               --          --         N           N           N           
  *P*                         0.017                                                                                  NS                                             
  **Ferritin (ng/mL)**                                                                                                                                              119.5
  N total                     73                           14                            31              11          11         13          56          15          
  Mean                        151.4                        182.4                         64.0            394.7       179.1      351.3       372.2       802.2       
  N (%) over cut-off          4 (6.1)                      3 (27.3)                      4 (12.9)        8 (72.7)    5 (45.5)   10 (76.9)   37 (66.1)   14 (93.3)   
  Association with outcome    N                            N                             N               N           --         N           N           N           
  *P*                         NS                                                                                     NS                                             
  **NSE (ng/mL)**                                                                                                                                                   200.0
  N total                     66                           11                            28              7           10         12          51          12          
  Mean                        69.9                         158.1                         65.8            152.7       99.0       366.2       165.2       243.2       
  N (%) over cut-off          4 (6.1)                      3 (27.3)                      2 (7.1)         2 (28.6)    0 (0.0)    6 (50.0)    10 (19.6)   5 (41.7)    
  Association with outcome    N                            N                             N               N           --         N           Y           N           
  *P*                         NS                                                                                     0.01                                           
  **LDH (IU/Ml)**                                                                                                                                                   1300/2500[a](#tfn4-ott-5-417){ref-type="table-fn"}
  N total                     75                           14                            32              11          12         14          56          16          
  Mean                        782.4                        2495.2                        882.4           3449.1      1020.8     5121.3      1367.0      4059.2      
  N (%) over cut-off          7 (9.3)                      11 (78.6)                     7 (21.9)        9 (81.8)    3 (25.0)   12 (85.7)   20 (37.5)   14 (87.5)   
  Association with outcome    Y                            N                             Y               N           --         N           Y           N           
  *P*                         0.0001                                                                                 0.0001                                         

**Note:**

For localized/metastatic group.

**Abbreviations:** A, amplified; HVA, homovanillic acid; LDH, lactate dehydrogenase; N, no, as determined by multivariate analysis; NA, not amplified; NB, neuroblastoma; NS, not significant; NSE, neuron-specific enolase; VMA, vanillylmandelic acid; Y, yes, as determined by multivariate analysis.

[^1]: On behalf of the Italian Association of Pediatric Hematology and Oncology (AIEOP)
